MaÃ«l Heiblig

List of Publications by Year
in descending order

28 papers	910 citations	759233 12 h-index	526287 27 g-index
29 all docs	29 docs citations	29 times ranked	991 citing authors

#	Article	IF	Citations
1	Azacitidine for patients with Vacuoles, E1 Enzyme, Xâ€linked, Autoinflammatory, Somatic syndrome (VEXAS) and myelodysplastic syndrome: data from the French VEXAS registry. British Journal of Haematology, 2022, 196, 969-974.	2.5	85
2	Further characterization of clinical and laboratory features in VEXAS syndrome: largeâ€scale analysis of a multicentre case series of 116 French patients*. British Journal of Dermatology, 2022, 186, 564-574.	1.5	174
3	Successful allogeneic hematopoietic stem cell transplantation in patients with VEXAS syndrome: a 2-center experience. Blood Advances, 2022, 6, 998-1003.	5.2	88
4	Class I/Class II HLA Evolutionary Divergence Ratio Is an Independent Marker Associated With Disease-Free and Overall Survival After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia. Frontiers in Immunology, 2022, 13, 841470.	4.8	9
5	Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study. Blood, 2022, 140, 927-931.	1.4	86
6	Antibody-based therapy for acute myeloid leukemia: a review of phase 2 and 3 trials. Expert Opinion on Emerging Drugs, 2022, 27, 169-185.	2.4	1
7	Therapeutic options in VEXAS syndrome: insights from a retrospective series. Blood, 2021, 137, 3682-3684.	1.4	145
8	The Impact of DNMT3A Status on NPM1 MRD Predictive Value and Survival in Elderly AML Patients Treated Intensively. Cancers, 2021, 13, 2156.	3.7	4
9	Allogenic Stem Cell Transplantation Abrogates Negative Impact on Outcome of AML Patients with KMT2A Partial Tandem Duplication. Cancers, 2021, 13, 2272.	3.7	3
10	Measurable residual disease including AML leukemia stem cell flow evaluation of CPX-351 therapy by multi-parameter flow cytometry. Leukemia Research, 2021, 111, 106673.	0.8	6
11	Enasidenib for the treatment of relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase 2 mutation. Expert Review of Precision Medicine and Drug Development, 2020, 5, 421-428.	0.7	3
12	Acute Promyelocytic Leukemia. Cancers, 2020, 12, 3718.	3.7	2
13	LYON-UNIVERSITY HOSPITAL EXPERIENCE WITH GEMTUZUMAB OZOGAMICIN THERAPY IN ACUTE MYELOID LEUKEMIA: A â€˜REAL-LIFEâ€™ STUDY. Mediterranean Journal of Hematology and Infectious Diseases, 2020, 12, e2020020.	1.3	4
14	An evaluation of glasdegib for the treatment of acute myelogenous leukemia. Expert Opinion on Pharmacotherapy, 2020, 21, 523-530.	1.8	15
15	Emerging pharmacotherapies for elderly acute myeloid leukemia patients. Expert Review of Hematology, 2020, 13, 619-643.	2.2	7
16	Prognostic Value of Genetic Alterations in Elderly Patients with Acute Myeloid Leukemia: A Single Institution Experience. Cancers, 2019, 11, 570.	3.7	14
17	Impact of NPM1 mutation subtypes on treatment outcome in AML: The Lyon-University Hospital experience. Leukemia Research, 2019, 76, 29-32.	0.8	2
18	Elderly Patients (Age 70 Years or Older) With Secondary Acute Myeloid Leukemia or Acute Myeloid Leukemia Developed Concurrently to Another Malignant Disease. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, e211-e218.	0.4	5

#	Article	IF	Citations
19	Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib. Nature Medicine, 2018, 24, 1167-1177.	30.7	157
20	Treatment patterns and comparative effectiveness in elderly acute myeloid leukemia patients (age 70) Tj ETQq0 0 0 rgBT /Overlock 10 T	1.3	12
21	Acute myeloid leukemia in the elderly (age 70 yr or older): longâ€term survivors. European Journal of Haematology, 2017, 98, 134-141.	2.2	9
22	TREATMENT WITH LOW-DOSE CYTARABINE IN ELDERLY PATIENTS (AGE 70 YEARS OR OLDER) WITH ACUTE MYELOID LEUKEMIA: A SINGLE INSTITUTION EXPERIENCE. Mediterranean Journal of Hematology and Infectious Diseases, 2016, 8, 2016009.	1.3	17
23	Diagnostic and treatment of adult Philadelphia chromosome-positive acute lymphoblastic leukemia. International Journal of Hematologic Oncology, 2016, 5, 77-90.	1.6	6
24	The development of agents targeting the BCR-ABL tyrosine kinase as Philadelphia chromosome-positive acute lymphoblastic leukemia treatment. Expert Opinion on Drug Discovery, 2016, 11, 1061-1070.	5.0	9
25	Effect of Age on Treatment Decision-Making in Elderly Patients With Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 477-483.	0.4	18
26	Effect of Initial Body Mass Index on Survival Outcome of Patients With Acute Leukemia: AÂSingle-Center Retrospective Study. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S7-S13.	0.4	8
27	Subcutaneous omacetaxine mepesuccinate in patients with chronic myeloid leukemia in tyrosine kinase inhibitor-resistant patients: Review and perspectives. Leukemia Research, 2014, 38, 1145-1153.	0.8	21
28	Decitabine for the treatment of adult patients (age â‰¥65 years) with newly diagnosedde novoor secondary acute myeloid leukemia. International Journal of Hematologic Oncology, 2013, 2, 305-314.	1.6	0